You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameClodronate
Accession NumberDB00720  (APRD00639)
TypeSmall Molecule
GroupsApproved, Investigational, Vet Approved
DescriptionA diphosphonate which affects calcium metabolism. It inhibits bone resorption and soft tissue calcification. [PubChem]
Structure
Thumb
Synonyms
(Dichloro-phosphono-methyl)-phosphonic acid
(Dichloromethylene)bisphosphonic acid
(Dichloromethylene)diphosphonic acid
Acide Clodronique
Acido Clodronico
Acidum Clodronicum
Clodronate
Clodronsaeure
Clodronsäure
Dichloromethanediphosphonic acid
Dichloromethylene-1,1-bisphosphonic acid
Dichloromethylene-1,1-diphosphonic acid
Dichloromethylidene diphosphonate
External Identifiers
  • BM 06.011
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BonefosSolution60 mgIntravenousBayer Inc1992-12-31Not applicableCanada
BonefosCapsule400 mgOralBayer Inc1992-12-31Not applicableCanada
ClasteonCapsule400 mgOralSunovion Pharmaceuticals Canada Inc2004-05-13Not applicableCanada
Ostac Cap 400mgCapsule400 mgOralHoffmann La Roche Limited1994-12-312006-10-11Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
LodronatBoehringer Ingelheim
LoronRoche
LytosRoche
OstacRoche
SindronatSindan
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Clodronate disodium
ThumbNot applicableDBSALT000972
Clodronate disodium tetrahydrate
ThumbNot applicableDBSALT001199
Categories
UNII0813BZ6866
CAS number10596-23-3
WeightAverage: 244.892
Monoisotopic: 243.886016298
Chemical FormulaCH4Cl2O6P2
InChI KeyACSIXWWBWUQEHA-UHFFFAOYSA-N
InChI
InChI=1S/CH4Cl2O6P2/c2-1(3,10(4,5)6)11(7,8)9/h(H2,4,5,6)(H2,7,8,9)
IUPAC Name
[dichloro(phosphono)methyl]phosphonic acid
SMILES
OP(O)(=O)C(Cl)(Cl)P(O)(O)=O
Pharmacology
IndicationFor the management of hypercalcemia of malignancy and as an adjunct in the management of osteolysis resulting from bone metastases of malignant tumors.
Structured Indications
PharmacodynamicsClodronate is a first generation (non-nitrogenous) bisphosphonate in the same family as etidronate and tiludronate. Clodronate affects calcium metabolism and inhibits bone resorption and soft tissue calcification. Of the clodronate that is resorbed (from oral preparation) or infused (for intravenous drugs), about 50% is excreted unchanged by the kidney. The remainder has a very high affinity for bone tissue, and is rapidly absorbed onto the bone surface. Clodronate has been shown to prevent or delay skeletal-related events and decrease bone pain as well as normalize calcium levels in the presence of hypercalcemia.
Mechanism of actionThe bisphosphonate group binds strongly to the bone mineral, hydroxyapatite. This explains the specific pharmacological action of these compounds on mineralized tissues, especially bone. The exact mechanism of action of clodronate is not known, however it is known that it does not inhibit protein isoprenylation but can be metabolized intracellularly to a β-γ-methylene (AppCp-type) analog of ATP (AppCCl2p), which is cytotoxic to macrophages in vitro. Inhibition of the ADP/ATP translocase by the metabolite AppCCl2p is a likely route by which clodronate causes osteoclast apoptosis and inhibits bone resorption. Recently, the slime mold Dictyostelium discoideum was shown to take up bisphosphonates by pinocytosis. In these cells, clodronate, but not other pharmacologically active bisphosphonates, was incorporated into adenine nucleotides, which could potentially explain why this bisphosphonate sometimes seems to act differently than the other bisphosphonates. Clodronate, like all biphosphonates, also binds protein-tyrosine-phosphatase.
TargetKindPharmacological actionActionsOrganismUniProt ID
ADP/ATP translocase 1Proteinyes
inhibitor
HumanP12235 details
ADP/ATP translocase 2Proteinyes
inhibitor
HumanP05141 details
ADP/ATP translocase 3Proteinyes
inhibitor
HumanP12236 details
HydroxylapatiteSmall moleculeyes
antagonist
Humannot applicabledetails
Related Articles
AbsorptionAfter oral administration, absorption is estimated at 1–3% of the ingested dose because of the low uptake from the gastrointestinal tract.
Volume of distributionNot Available
Protein binding2%-36%
Metabolism

Clodronate is not metabolized in humans.

Route of eliminationNot Available
Half lifeApproximately 13 hours.
ClearanceNot Available
ToxicityDecreases in serum calcium following substantial overdosage may be expected in some patients. Signs and symptoms of hypocalcemia also may occur in some of these patients.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Clodronate.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Clodronate.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Clodronate.Approved, Vet Approved
AclarubicinAclarubicin may increase the hypocalcemic activities of Clodronate.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Clodronate.Approved
Aluminum hydroxideThe serum concentration of Clodronate can be decreased when it is combined with Aluminum hydroxide.Approved
Aluminum phosphateThe serum concentration of Clodronate can be decreased when it is combined with Aluminum phosphate.Approved
AmikacinAmikacin may increase the hypocalcemic activities of Clodronate.Approved, Vet Approved
AmrubicinAmrubicin may increase the hypocalcemic activities of Clodronate.Approved, Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Clodronate.Investigational
annamycinannamycin may increase the hypocalcemic activities of Clodronate.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Clodronate.Approved
ApramycinApramycin may increase the hypocalcemic activities of Clodronate.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Clodronate.Approved, Investigational
ArbekacinArbekacin may increase the hypocalcemic activities of Clodronate.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Clodronate.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Clodronate.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Clodronate.Approved, Investigational
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Clodronate.Withdrawn
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Clodronate.Investigational
Bismuth SubcitrateThe serum concentration of Clodronate can be decreased when it is combined with Bismuth Subcitrate.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Clodronate.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Clodronate.Investigational
CalciumThe serum concentration of Clodronate can be decreased when it is combined with Calcium.Nutraceutical
Calcium AcetateThe serum concentration of Clodronate can be decreased when it is combined with Calcium Acetate.Approved
Calcium carbonateThe serum concentration of Clodronate can be decreased when it is combined with Calcium carbonate.Approved
Calcium ChlorideThe serum concentration of Clodronate can be decreased when it is combined with Calcium Chloride.Approved
Calcium citrateThe serum concentration of Clodronate can be decreased when it is combined with Calcium citrate.Approved
Calcium glubionateThe serum concentration of Clodronate can be decreased when it is combined with Calcium glubionate.Approved
Calcium GluceptateThe serum concentration of Clodronate can be decreased when it is combined with Calcium Gluceptate.Approved
Calcium gluconateThe serum concentration of Clodronate can be decreased when it is combined with Calcium gluconate.Approved, Vet Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Clodronate.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Clodronate.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Clodronate.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Clodronate.Approved, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Clodronate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Clodronate.Investigational
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Clodronate.Investigational
DaunorubicinDaunorubicin may increase the hypocalcemic activities of Clodronate.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Clodronate is combined with Deferasirox.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Clodronate.Approved, Vet Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Clodronate.Approved
DihydrostreptomycinDihydrostreptomycin may increase the hypocalcemic activities of Clodronate.Vet Approved
DoxorubicinDoxorubicin may increase the hypocalcemic activities of Clodronate.Approved, Investigational
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Clodronate.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Clodronate.Investigational
E6201The risk or severity of adverse effects can be increased when E6201 is combined with Clodronate.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Clodronate.Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Clodronate.Approved
EpirubicinEpirubicin may increase the hypocalcemic activities of Clodronate.Approved
EsomeprazoleThe therapeutic efficacy of Clodronate can be decreased when used in combination with Esomeprazole.Approved, Investigational
EstramustineThe serum concentration of Estramustine can be increased when it is combined with Clodronate.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Clodronate.Approved, Investigational
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Clodronate.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Clodronate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Clodronate.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Clodronate.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Clodronate.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Clodronate.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Clodronate.Approved
Ferric CitrateThe serum concentration of Clodronate can be decreased when it is combined with Ferric Citrate.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Clodronate.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Clodronate.Vet Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Clodronate.Approved, Investigational
FramycetinFramycetin may increase the hypocalcemic activities of Clodronate.Approved
GeneticinGeneticin may increase the hypocalcemic activities of Clodronate.Experimental
GentamicinGentamicin may increase the hypocalcemic activities of Clodronate.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the hypocalcemic activities of Clodronate.Experimental
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Clodronate.Investigational
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Clodronate.Investigational
Hygromycin BHygromycin B may increase the hypocalcemic activities of Clodronate.Vet Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Clodronate.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Clodronate.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Clodronate.Approved
IdarubicinIdarubicin may increase the hypocalcemic activities of Clodronate.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Clodronate.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Clodronate.Withdrawn
INNO-206INNO-206 may increase the hypocalcemic activities of Clodronate.Investigational
Iron saccharateThe serum concentration of Clodronate can be decreased when it is combined with Iron saccharate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Clodronate.Withdrawn
KanamycinKanamycin may increase the hypocalcemic activities of Clodronate.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Clodronate.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Clodronate.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Clodronate.Approved
LansoprazoleThe therapeutic efficacy of Clodronate can be decreased when used in combination with Lansoprazole.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Clodronate.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Clodronate.Investigational
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Clodronate.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Clodronate.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Clodronate.Approved, Investigational
Magnesium carbonateThe serum concentration of Clodronate can be decreased when it is combined with Magnesium carbonate.Approved
Magnesium hydroxideThe serum concentration of Clodronate can be decreased when it is combined with Magnesium hydroxide.Approved
Magnesium oxideThe serum concentration of Clodronate can be decreased when it is combined with Magnesium oxide.Approved
Magnesium salicylateThe serum concentration of Clodronate can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium SulfateThe serum concentration of Clodronate can be decreased when it is combined with Magnesium Sulfate.Approved, Vet Approved
Magnesium TrisilicateThe serum concentration of Clodronate can be decreased when it is combined with Magnesium Trisilicate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Clodronate.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clodronate.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Clodronate.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Clodronate.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Clodronate.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Clodronate.Withdrawn
MetrizamideMetrizamide may increase the hypocalcemic activities of Clodronate.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Clodronate.Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Clodronate.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clodronate.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Clodronate.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Clodronate.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Clodronate.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Clodronate.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Clodronate.Investigational
NeamineNeamine may increase the hypocalcemic activities of Clodronate.Experimental
NeomycinNeomycin may increase the hypocalcemic activities of Clodronate.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Clodronate.Approved
NetilmicinNetilmicin may increase the hypocalcemic activities of Clodronate.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Clodronate.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Clodronate.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Clodronate.Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clodronate.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Clodronate.Approved
OmeprazoleThe therapeutic efficacy of Clodronate can be decreased when used in combination with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Clodronate.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Clodronate.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Clodronate.Withdrawn
PantoprazoleThe therapeutic efficacy of Clodronate can be decreased when used in combination with Pantoprazole.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Clodronate.Approved
ParomomycinParomomycin may increase the hypocalcemic activities of Clodronate.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Clodronate.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Clodronate.Approved, Investigational
PirarubicinPirarubicin may increase the hypocalcemic activities of Clodronate.Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Clodronate.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Clodronate.Approved, Investigational
PlicamycinPlicamycin may increase the hypocalcemic activities of Clodronate.Approved, Withdrawn
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Clodronate.Approved
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Clodronate.Investigational
PuromycinPuromycin may increase the hypocalcemic activities of Clodronate.Experimental
RabeprazoleThe therapeutic efficacy of Clodronate can be decreased when used in combination with Rabeprazole.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Clodronate.Experimental, Investigational
RibostamycinRibostamycin may increase the hypocalcemic activities of Clodronate.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Clodronate.Investigational, Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Clodronate.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Clodronate.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Clodronate.Approved
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Clodronate.Approved, Investigational
SisomicinSisomicin may increase the hypocalcemic activities of Clodronate.Investigational
SP1049CSP1049C may increase the hypocalcemic activities of Clodronate.Investigational
SpectinomycinSpectinomycin may increase the hypocalcemic activities of Clodronate.Approved, Vet Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Clodronate.Investigational
StreptomycinStreptomycin may increase the hypocalcemic activities of Clodronate.Approved, Vet Approved
StreptozocinStreptozocin may increase the hypocalcemic activities of Clodronate.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Clodronate.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Clodronate.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Clodronate.Approved, Withdrawn
TAK-390MRThe therapeutic efficacy of Clodronate can be decreased when used in combination with TAK-390MR.Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Clodronate.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Clodronate.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Clodronate.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Clodronate.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Clodronate.Investigational
TobramycinTobramycin may increase the hypocalcemic activities of Clodronate.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Clodronate.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Clodronate.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Clodronate.Approved, Investigational
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Clodronate.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Clodronate.Investigational, Withdrawn
ValrubicinValrubicin may increase the hypocalcemic activities of Clodronate.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Clodronate.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Clodronate.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Clodronate.Withdrawn
ZorubicinZorubicin may increase the hypocalcemic activities of Clodronate.Experimental
Food Interactions
  • Food decreases absorption. Take on an empty stomach.
References
Synthesis Reference

Fritz Demmer, Berthold Stemmle, “Clodronate-containing medicaments and a process for the preparation thereof.” U.S. Patent US4859472, issued September, 1980.

US4859472
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS Codes
  • 92:00.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (120 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8406
Blood Brain Barrier+0.9481
Caco-2 permeable-0.8956
P-glycoprotein substrateNon-substrate0.8597
P-glycoprotein inhibitor INon-inhibitor0.9701
P-glycoprotein inhibitor IINon-inhibitor0.9903
Renal organic cation transporterNon-inhibitor0.958
CYP450 2C9 substrateNon-substrate0.7693
CYP450 2D6 substrateNon-substrate0.8234
CYP450 3A4 substrateNon-substrate0.697
CYP450 1A2 substrateNon-inhibitor0.8539
CYP450 2C9 inhibitorNon-inhibitor0.8878
CYP450 2D6 inhibitorNon-inhibitor0.9091
CYP450 2C19 inhibitorNon-inhibitor0.8449
CYP450 3A4 inhibitorNon-inhibitor0.9061
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9743
Ames testNon AMES toxic0.7328
CarcinogenicityCarcinogens 0.6575
BiodegradationNot ready biodegradable0.927
Rat acute toxicity2.6142 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9321
hERG inhibition (predictor II)Non-inhibitor0.9427
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
CapsuleOral400 mg
SolutionIntravenous60 mg
Prices
Unit descriptionCostUnit
Bonefos 60 mg/ml13.69USD ml
Bonefos 400 mg Capsule2.04USD capsule
Clasteon 400 mg Capsule1.36USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point250 °CPhysProp
water solubility395 mg/LNot Available
logP-2.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility7.47 mg/mLALOGPS
logP0.16ALOGPS
logP-0.067ChemAxon
logS-1.5ALOGPS
pKa (Strongest Acidic)0.62ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area115.06 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity38.21 m3·mol-1ChemAxon
Polarizability15.3 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as bisphosphonates. These are organic compounds containing two phosphonate groups linked together through a carbon atoms.
KingdomOrganic compounds
Super ClassOrganophosphorus compounds
ClassOrganic phosphonic acids and derivatives
Sub ClassBisphosphonates
Direct ParentBisphosphonates
Alternative Parents
Substituents
  • Bisphosphonate
  • Organophosphonic acid
  • Halomethane
  • Hydrocarbon derivative
  • Organochloride
  • Organohalogen compound
  • Alkyl halide
  • Alkyl chloride
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Adenine transmembrane transporter activity
Specific Function:
Catalyzes the exchange of cytoplasmic ADP with mitochondrial ATP across the mitochondrial inner membrane.
Gene Name:
SLC25A4
Uniprot ID:
P12235
Molecular Weight:
33064.265 Da
References
  1. Lehenkari PP, Kellinsalmi M, Napankangas JP, Ylitalo KV, Monkkonen J, Rogers MJ, Azhayev A, Vaananen HK, Hassinen IE: Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol. 2002 May;61(5):1255-62. [PubMed:11961144 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Ubiquitin protein ligase binding
Specific Function:
Catalyzes the exchange of cytoplasmic ADP with mitochondrial ATP across the mitochondrial inner membrane. As part of the mitotic spindle-associated MMXD complex it may play a role in chromosome segregation.
Gene Name:
SLC25A5
Uniprot ID:
P05141
Molecular Weight:
32851.965 Da
References
  1. Lehenkari PP, Kellinsalmi M, Napankangas JP, Ylitalo KV, Monkkonen J, Rogers MJ, Azhayev A, Vaananen HK, Hassinen IE: Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol. 2002 May;61(5):1255-62. [PubMed:11961144 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Atp:adp antiporter activity
Specific Function:
Catalyzes the exchange of cytoplasmic ADP with mitochondrial ATP across the mitochondrial inner membrane. May participate in the formation of the permeability transition pore complex (PTPC) responsible for the release of mitochondrial products that triggers apoptosis.
Gene Name:
SLC25A6
Uniprot ID:
P12236
Molecular Weight:
32866.025 Da
References
  1. Lehenkari PP, Kellinsalmi M, Napankangas JP, Ylitalo KV, Monkkonen J, Rogers MJ, Azhayev A, Vaananen HK, Hassinen IE: Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol. 2002 May;61(5):1255-62. [PubMed:11961144 ]
Kind
Small molecule
Organism
Human
Pharmacological action
yes
Actions
antagonist
References
  1. Ganguli A, Steward C, Butler SL, Philips GJ, Meikle ST, Lloyd AW, Grant MH: Bacterial adhesion to bisphosphonate coated hydroxyapatite. J Mater Sci Mater Med. 2005 Apr;16(4):283-7. [PubMed:15803271 ]
  2. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH: Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006 May;38(5):617-27. Epub 2005 Jul 20. [PubMed:16046206 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Liu L, Igarashi K, Kanzaki H, Chiba M, Shinoda H, Mitani H: Clodronate inhibits PGE(2) production in compressed periodontal ligament cells. J Dent Res. 2006 Aug;85(8):757-60. [PubMed:16861295 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23